Novo Nordisk Beats Q3 Profit Expectations, Boosts GLP‑1 Growth & Share‑Repurchase Plan
Novo Nordisk boosts full‑year outlook as GLP‑1 sales surge, driving a 27% profit jump and share rally—strong earnings, share‑repurchase and a dominant obesity drug lead.
2 minutes to read